Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | - USD | 100.0% |
| 2022 | -212.65 Thousand USD | 57.25% |
| 2021 | -497.47 Thousand USD | -269.04% |
| 2020 | 294.3 Thousand USD | 376.62% |
| 2019 | 61.74 Thousand USD | 174.96% |
| 2018 | -82.36 Thousand USD | -336.69% |
| 2017 | -18.86 Thousand USD | -127.41% |
| 2016 | 68.8 Thousand USD | 110.22% |
| 2015 | -673.4 Thousand USD | 4.14% |
| 2014 | -702.52 Thousand USD | -422.29% |
| 2013 | -134.5 Thousand USD | -207.66% |
| 2012 | 124.94 Thousand USD | 154.38% |
| 2011 | -229.73 Thousand USD | 28.93% |
| 2010 | -323.26 Thousand USD | 73.69% |
| 2009 | -1.22 Million USD | 46.26% |
| 2008 | -2.28 Million USD | -74.91% |
| 2007 | -1.3 Million USD | 0.0% |
| 2006 | - USD | 100.0% |
| 2005 | -130.3 Thousand USD | -105.11% |
| 2004 | 2.55 Million USD | -7.22% |
| 2003 | 2.74 Million USD | -71.64% |
| 2002 | 9.69 Million USD | 6.26% |
| 2001 | 9.12 Million USD | 3.83% |
| 2000 | 8.78 Million USD | 7.47% |
| 1999 | 8.17 Million USD | 54.48% |
| 1998 | 5.29 Million USD | 1011.82% |
| 1997 | -580.38 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q1 | 8222.00 USD | 103.87% |
| 2023 Q2 | 151.92 Thousand USD | 1747.81% |
| 2023 FY | - USD | 100.0% |
| 2023 Q3 | -7915.00 USD | -105.21% |
| 2023 Q4 | - USD | 100.0% |
| 2022 FY | -212.65 Thousand USD | 57.25% |
| 2022 Q3 | -148.7 Thousand USD | 59.47% |
| 2022 Q4 | -212.65 Thousand USD | -43.01% |
| 2022 Q2 | -366.92 Thousand USD | -7.67% |
| 2022 Q1 | -340.77 Thousand USD | 31.5% |
| 2021 Q2 | 354.91 Thousand USD | 6.36% |
| 2021 Q4 | -497.47 Thousand USD | 20.28% |
| 2021 Q3 | -624.02 Thousand USD | -275.82% |
| 2021 Q1 | 333.69 Thousand USD | 13.39% |
| 2021 FY | -497.47 Thousand USD | -269.04% |
| 2020 Q3 | 296.3 Thousand USD | 1.96% |
| 2020 FY | 294.3 Thousand USD | 376.62% |
| 2020 Q1 | 168.61 Thousand USD | 173.07% |
| 2020 Q2 | 290.62 Thousand USD | 72.36% |
| 2020 Q4 | 294.3 Thousand USD | -0.68% |
| 2019 FY | 61.74 Thousand USD | 174.96% |
| 2019 Q1 | -115.82 Thousand USD | -40.62% |
| 2019 Q3 | 155.48 Thousand USD | 5309.99% |
| 2019 Q4 | 61.74 Thousand USD | -60.29% |
| 2019 Q2 | 2874.00 USD | 102.48% |
| 2018 Q4 | -82.36 Thousand USD | 73.66% |
| 2018 Q1 | -178.04 Thousand USD | -843.96% |
| 2018 Q3 | -312.7 Thousand USD | -535.29% |
| 2018 FY | -82.36 Thousand USD | -336.69% |
| 2018 Q2 | 71.84 Thousand USD | 140.35% |
| 2017 FY | -18.86 Thousand USD | -127.41% |
| 2017 Q3 | 107.91 Thousand USD | 230.81% |
| 2017 Q4 | -18.86 Thousand USD | -117.48% |
| 2017 Q2 | -82.49 Thousand USD | -16.02% |
| 2017 Q1 | -71.1 Thousand USD | 2.02% |
| 2016 Q2 | -266.75 Thousand USD | 43.26% |
| 2016 Q4 | -72.56 Thousand USD | 21.49% |
| 2016 FY | 68.8 Thousand USD | 110.22% |
| 2016 Q1 | -470.1 Thousand USD | 30.19% |
| 2016 Q3 | -92.42 Thousand USD | 65.35% |
| 2015 FY | -673.4 Thousand USD | 4.14% |
| 2015 Q1 | -829.53 Thousand USD | -18.08% |
| 2015 Q3 | -499.41 Thousand USD | 12.76% |
| 2015 Q4 | -673.4 Thousand USD | -34.84% |
| 2015 Q2 | -572.48 Thousand USD | 30.99% |
| 2014 Q1 | -192.4 Thousand USD | -43.04% |
| 2014 Q2 | -556.65 Thousand USD | -189.31% |
| 2014 Q3 | -685.02 Thousand USD | -23.06% |
| 2014 FY | -702.52 Thousand USD | -422.29% |
| 2014 Q4 | -702.52 Thousand USD | -2.55% |
| 2013 Q3 | -334.66 Thousand USD | -308.3% |
| 2013 Q4 | -134.5 Thousand USD | 59.81% |
| 2013 Q2 | 160.67 Thousand USD | 274.46% |
| 2013 FY | -134.5 Thousand USD | -207.66% |
| 2013 Q1 | 42.9 Thousand USD | -65.66% |
| 2012 FY | 124.94 Thousand USD | 154.38% |
| 2012 Q1 | -85.37 Thousand USD | 62.84% |
| 2012 Q2 | -3906.00 USD | 95.43% |
| 2012 Q3 | 135.09 Thousand USD | 3558.53% |
| 2012 Q4 | 124.94 Thousand USD | -7.51% |
| 2011 FY | -229.73 Thousand USD | 28.93% |
| 2011 Q4 | -229.73 Thousand USD | 46.4% |
| 2011 Q3 | -428.63 Thousand USD | 36.91% |
| 2011 Q2 | -679.45 Thousand USD | 27.11% |
| 2011 Q1 | -932.16 Thousand USD | -188.36% |
| 2010 Q3 | -502.98 Thousand USD | 30.45% |
| 2010 Q4 | -323.26 Thousand USD | 35.73% |
| 2010 FY | -323.26 Thousand USD | 73.69% |
| 2010 Q1 | -994.4 Thousand USD | 19.07% |
| 2010 Q2 | -723.21 Thousand USD | 27.27% |
| 2009 Q3 | -1.46 Million USD | 16.04% |
| 2009 Q2 | -1.74 Million USD | 13.19% |
| 2009 Q4 | -1.22 Million USD | 16.24% |
| 2009 Q1 | -2.01 Million USD | 11.97% |
| 2009 FY | -1.22 Million USD | 46.26% |
| 2008 Q3 | -2.62 Million USD | 10.75% |
| 2008 FY | -2.28 Million USD | -74.91% |
| 2008 Q1 | -3.31 Million USD | -153.95% |
| 2008 Q2 | -2.94 Million USD | 11.33% |
| 2008 Q4 | -2.28 Million USD | 12.96% |
| 2007 Q3 | -1.47 Million USD | 16.06% |
| 2007 Q1 | -2.03 Million USD | 0.0% |
| 2007 Q2 | -1.75 Million USD | 13.73% |
| 2007 Q4 | -1.3 Million USD | 11.22% |
| 2007 FY | -1.3 Million USD | 0.0% |
| 2006 FY | - USD | 100.0% |
| 2006 Q1 | -104.95 Thousand USD | 19.45% |
| 2006 Q2 | -353.84 Thousand USD | -237.13% |
| 2006 Q3 | -287.55 Thousand USD | 18.73% |
| 2006 Q4 | - USD | 100.0% |
| 2005 Q3 | 2.6 Million USD | 2.79% |
| 2005 FY | -130.3 Thousand USD | -105.11% |
| 2005 Q1 | 2.58 Million USD | 1.42% |
| 2005 Q4 | -130.3 Thousand USD | -105.01% |
| 2005 Q2 | 2.53 Million USD | -2.1% |
| 2004 FY | 2.55 Million USD | -7.22% |
| 2004 Q4 | 2.55 Million USD | -3.5% |
| 2004 Q3 | 2.64 Million USD | 1.24% |
| 2004 Q2 | 2.61 Million USD | 0.55% |
| 2004 Q1 | 2.59 Million USD | -5.54% |
| 2003 Q1 | 9.75 Million USD | 0.6% |
| 2003 FY | 2.74 Million USD | -71.64% |
| 2003 Q2 | 2.97 Million USD | -69.53% |
| 2003 Q3 | 2.92 Million USD | -1.41% |
| 2003 Q4 | 2.74 Million USD | -6.15% |
| 2002 Q4 | 9.69 Million USD | 0.8% |
| 2002 FY | 9.69 Million USD | 6.26% |
| 2002 Q1 | 8.98 Million USD | -1.48% |
| 2002 Q2 | 9.35 Million USD | 4.08% |
| 2002 Q3 | 9.61 Million USD | 2.81% |
| 2001 Q4 | 9.12 Million USD | 5.74% |
| 2001 FY | 9.12 Million USD | 3.83% |
| 2001 Q2 | 8.59 Million USD | -1.27% |
| 2001 Q1 | 8.7 Million USD | -0.87% |
| 2001 Q3 | 8.62 Million USD | 0.33% |
| 2000 Q2 | 7.67 Million USD | -10.41% |
| 2000 Q1 | 8.56 Million USD | 4.76% |
| 2000 Q3 | 8.44 Million USD | 10.0% |
| 2000 FY | 8.78 Million USD | 7.47% |
| 2000 Q4 | 8.78 Million USD | 4.09% |
| 1999 FY | 8.17 Million USD | 54.48% |
| 1999 Q1 | 5.11 Million USD | -3.28% |
| 1999 Q4 | 8.17 Million USD | 65.62% |
| 1999 Q2 | 4.16 Million USD | -18.53% |
| 1999 Q3 | 4.93 Million USD | 18.37% |
| 1998 Q3 | -279.4 Thousand USD | 78.58% |
| 1998 Q1 | -781.08 Thousand USD | 0.0% |
| 1998 FY | 5.29 Million USD | 1011.82% |
| 1998 Q2 | -1.3 Million USD | -67.03% |
| 1998 Q4 | 5.29 Million USD | 1994.02% |
| 1997 FY | -580.38 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 100.0% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.0% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 305 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 100.0% |
| Qrons Inc. | 351.42 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -5.72 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 100.0% |
| Mesoblast Limited | 55.85 Million USD | 100.0% |
| Marizyme, Inc. | 18.56 Million USD | 100.0% |
| Genus plc | 190.6 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.0% |
| Pharming Group N.V. | 109.8 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 100.0% |
| ContraFect Corporation | -6.02 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.0% |
| IMV Inc. | 7.67 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 90.04 USD | 100.0% |
| ONE Bio Corp. | 9.04 Million USD | 100.0% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 100.0% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 1.36 Million USD | 100.0% |
| Q BioMed Inc. | 4.06 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.0% |
| Biomind Labs Inc. | 711.4 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.0% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.0% |
| GB Sciences, Inc. | 1.74 Million USD | 100.0% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 100.0% |
| HST Global, Inc. | 96.79 Thousand USD | 100.0% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 100.0% |
| Halberd Corporation | 144.72 Thousand USD | 100.0% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.0% |
| Agentix Corp. | 37.63 Thousand USD | 100.0% |
| Resverlogix Corp. | 6.45 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -2.02 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.0% |
| AVAX Technologies, Inc. | -5.9 Million USD | 100.0% |
| Zenith Capital Corp. | 10.06 Thousand USD | 100.0% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 100.0% |
| Kadimastem Ltd | -253.1 Thousand USD | 100.0% |
| Helix BioMedix, Inc. | -2.57 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.0% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 100.0% |
| LadRx Corporation | -2.03 Million USD | 100.0% |
| Cell Source, Inc. | 9.23 Million USD | 100.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.17 Million USD | 100.0% |
| Affymax, Inc. | -5.59 Million USD | 100.0% |
| Itoco Inc. | 228.3 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.0% |
| Mobile Lads Corp. | 484.23 Thousand USD | 100.0% |
| CytoDyn Inc. | 20.26 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 100.0% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.0% |
| SYBLEU INC | 473.71 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.0% |
| International Stem Cell Corporation | 2.59 Million USD | 100.0% |
| Bioxytran, Inc. | 1.89 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 3.43 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 772.6 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 100.0% |
| Neutra Corp. | 52.18 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 100.0% |
| PureTech Health plc | -167.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 100.0% |
| IXICO plc | -4.44 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.0% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 100.0% |